Race Oncology CSO Dr Daniel Tillett discusses the bright future for Zantrene

We speak with Dr Daniel Tillett, Chief Scientific Officer of Race Oncology, about the potential market and efficacy of their drug, Zantrene, which seems likely to change the cancer treatment landscape in the near future.